Life Biosciences

Before joining as CSO, Dr. Sharon Rosenzweig-Lipson had a long history of setting goals and achieving them, dating back to first grade! Hear about her experiences as a female leader, mentor and mother on Cara Pepler's HER SCRIPT Podcast: https://apple.co/3xvI8aa

🎉 We are thrilled to introduce our new Junior Project Manager, Sadie Crocker, to the Life Biosciences team! After interning with us for two years, Sadie has made significant contributions in research and data analysis. Her dedication has driven positive change, and we are excited to see her excel in her new role. Join us in congratulating Sadie on joining the team! #NewHire

✈️ Life Bio is going to Europe! Sharon Rosenzweig-Lipson, Ph.D., our CSO, is presenting on our partial epigenetic reprogramming platform for #CellularRejuvenation at the 2024 Systems Aging Gordon Research Conferences in Barcelona. Learn more about the conference here: https://bit.ly/4chO7OH

Since 1942, advances in the #epigenetics field have paved the way toward applications that once seemed unattainable. Our CSO, Dr. Sharon Rosenzweig-Lipson, discusses our partial epigenetic reprogramming platform and clinical progress in this Genetic Engineering & Biotechnology News article: https://lnkd.in/ePfsUzfV 

Our CEO Jerry McLaughlin and CSO Sharon Rosenzweig-Lipson sat down with Hannah Green at Boston Business Journal to discuss our progress towards developing therapeutics to reverse and prevent #AgeRelatedDiseases through cellular rejuvenation. We are proud to be part of the booming Boston ecosystem! Read the article here: https://lnkd.in/eTKd9dQk 

Aging is the biggest modifiable risk factor for chronic diseases. At Life Bio, we target the underlying biology of aging to treat #AgeRelatedDiseases through Sharon Rosenzweig-Lipson in this issue of Drug Discovery World: https://brnw.ch/21wIcn5

Boston is a #Biotech hub, and we’re honored to be part of Labiotech.eu’s Twelve Hottest Biotech Companies in the Boston Area! We look forward to continuing to drive innovation as we develop treatments to reverse & prevent #AgeRelatedDisease. More here: https://lnkd.in/gvj5S4W2

Thanks to recent research, we now know that aging isn’t just a result of random wear and tear. At Life Bio, we are focused on targeting the biological mechanisms of aging to revert cells to a more youthful state to treat #AgeRelatedDiseases through #CellularRejuvenation. Hear more from our CSO Dr. Sharon Rosenzweig-Lipson in this Cell & Gene Podcast with Erin Harris: https://bit.ly/48QS62w 

In 2024, our CEO Jerry McLaughlin anticipates a growing interest in extending #healthspan. He expects a focus on the science underlying aging biology due to its clear link to disease pathogenesis. Read more on his outlook in this Scrip Asks series (subscribers only): https://brnw.ch/21wH0gM

Want to learn more about targeting #AgingBiology with therapeutics through #CellularRejuvenation? Our CEO Jerry McLaughlin provides his insights in this Drug Target Review article. Read about how we have validated our science in #PreclinicalStudies and what’s next for Life Bio: https://brnw.ch/21wFXwf